Cargando…

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease

WHAT IS KNOWN AND OBJECTIVE: Infliximab is an anti‐tumour necrosis factor agent used in the treatment of inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. While the use of infliximab is well established in the treatment of IBD, there are now four recently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rusch, Caroline, Wood, Marci, Kennedy, Amanda G., Tompkins, Bradley J., Frasca, Joseph D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825869/ https://www.ncbi.nlm.nih.gov/pubmed/36134561 http://dx.doi.org/10.1111/jcpt.13779

Ejemplares similares

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting
por: Checkley, L. Allyson, et al.
Publicado: (2018)

Infliximab-Related Infusion Reactions: Systematic Review
por: Lichtenstein, Lev, et al.
Publicado: (2015)

Immediate-type infliximab infusion reaction presenting as purpura
por: Soong, Laura, et al.
Publicado: (2018)

A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol
por: Ong, Wan Chee, et al.
Publicado: (2022)

Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study
por: Szymanska, Edyta, et al.
Publicado: (2021)

Predictors of infusion reactions during infliximab treatment in patients with arthritis
por: Kapetanovic, Meliha C, et al.
Publicado: (2006)

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Jagt, Jasmijn Z., et al.
Publicado: (2023)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study
por: Wang, Xiaolei, et al.
Publicado: (2019)

Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study
por: Abushamma, Suha, et al.
Publicado: (2023)

Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
por: Vimpolsek, Maja, et al.
Publicado: (2019)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion
por: Wang, Jingzhou, et al.
Publicado: (2018)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study
por: Viola, Anna, et al.
Publicado: (2017)

Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle
por: Seong, Gyeol, et al.
Publicado: (2020)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis
por: Lee, Shin-Seok, et al.
Publicado: (2021)

Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Development of anti-infliximab antibody is associated with reduced efficacy and infusion reaction in Behçet's disease with uveitis
por: Ishigatsubo, Y, et al.
Publicado: (2015)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)
por: Pérez‐Persona, Ernesto, et al.
Publicado: (2023)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
por: Mir, Fazia A., et al.
Publicado: (2018)

Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center
por: Park, Jiyeon Joy, et al.
Publicado: (2018)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2018)

Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
por: Martínez-Feito, Ana, et al.
Publicado: (2020)

The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta
por: Kaplan, Gilaad G, et al.
Publicado: (2020)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices
por: Bhat, Shubha, et al.
Publicado: (2021)

Chronic Inflammatory Demyelinating Polyneuropathy After Therapy With Infliximab Biosimilar
por: Larson, Jessica, et al.
Publicado: (2023)

Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab
por: Scaldaferri, Franco, et al.
Publicado: (2017)

Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
por: Huoponen, Saara, et al.
Publicado: (2020)

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
por: Pękala, Anna, et al.
Publicado: (2021)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar
por: Meijboom, Rosanne W., et al.
Publicado: (2023)

Linear IgA dermatosis after infliximab infusion for ulcerative colitis
por: Bryant, Kelli D., et al.
Publicado: (2016)

Implementation and Evaluation of a Standard Operating Procedure for Pediatric Infliximab Infusions
por: Kelly, Maureen M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_irtdiioqumk325vbvjrlnj6g1r